These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11796309)

  • 1. Antiandrogens in the treatment of priapism.
    Dahm P; Rao DS; Donatucci CF
    Urology; 2002 Jan; 59(1):138. PubMed ID: 11796309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen blockade for the treatment of high-flow priapism.
    Mwamukonda KB; Chi T; Shindel AW; Lue TF
    J Sex Med; 2010 Jul; 7(7):2532-7. PubMed ID: 20456623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priapism of ambiguous classification in a sickle cell patient.
    Hoffman S; Kaynan AM; Melman A
    Int J Impot Res; 2000 Feb; 12(1):59-63. PubMed ID: 10982314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation.
    Pierorazio PM; Bivalacqua TJ; Burnett AL
    J Androl; 2011; 32(4):371-4. PubMed ID: 21127306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer risk after anti-androgen treatment for priapism.
    Goetz T; Burnett AL
    Int Urol Nephrol; 2014 Apr; 46(4):757-60. PubMed ID: 24136185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report on idiopathic recurrent priapism.
    Wisard M; Aymon D; Jichlinski P; Praz V
    Andrologia; 2007 Dec; 39(6):261-2. PubMed ID: 18076427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 15. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF; Schellhammer PF; Johnson R; Carroll K; Kolvenbag GJ
    Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 17. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR; Fallon MA; Goode MJ
    Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
    Lunglmayr G
    Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 20. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
    Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.